Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptorDonghua Yin, Huiping Xu, Yali He, et al.Pharmaceuticals (Basel, Switzerland)|September 28, 2021
Targeting the Bromodomain of BRG-1/BRM Subunit of the SWI/SNF Complex Increases the Anticancer Activity of Temozolomide in GlioblastomaChuanhe Yang, Yinan Wang, Michelle M Sims, et al.Chemical Communications (Cambridge, England)|January 8, 2026
Metal- and photocatalyst-free CF<sub>3</sub>-modification of <i>N</i>-containing fusion skeletons in photo-flow chemistryTing Lv, Chenxi Gu, Yuchen Zhu, et al.The FEBS Journal|May 6, 2026
ACTR3 enhances the hyperproliferation of psoriatic keratinocytes by activating the TAK1-MK2-HSP27 pathwayJianxiao Xing, Junqin Li, Ying Wang, et al.The Science of the Total Environment|June 12, 2019
Immobilization of heavy metals in vegetable-growing soils using nano zero-valent iron modified attapulgite clayCongbin Xu, Jia Qi, Wenjie Yang, et al.International Journal of Molecular Sciences|March 6, 2021
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate CancerMichael L Mohler, Arunima Sikdar, Suriyan Ponnusamy, et al.Journal of Medicinal Chemistry|October 23, 2020
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate CancerYali He, Dong-Jin Hwang, Suriyan Ponnusamy, et al.Journal of Medicinal Chemistry|July 16, 2021
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate CancerYali He, Dong-Jin Hwang, Suriyan Ponnusamy, et al.Journal of Medicinal Chemistry|February 24, 2023
Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity against Enzalutamide-Resistant Prostate CancerDong-Jin Hwang, Yali He, Suriyan Ponnusamy, et al.Journal of Cellular and Molecular Medicine|August 18, 2023
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastomaChuanhe Yang, Yali He, Yinan Wang, et al.Pageof 6